scholarly journals Nationwide Rereview of Normal Cervical Cytologies before High-Grade Cervical Lesions or before Invasive Cervical Cancer

2021 ◽  
pp. 1-8
Author(s):  
Henrik Edvardsson ◽  
Jiangrong Wang ◽  
Bengt Andrae ◽  
Pär Sparén ◽  
Björn Strander ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Screening Program ◽  
Cervical Screening ◽  
Invasive Cervical Cancer ◽  
False Negative ◽  
Cancer Control ◽  
Adenocarcinoma In Situ ◽  
High Grade ◽  
Cervical Lesions ◽  
Normal Cytology

Sweden has experienced an unexpected &#x3e;30% increase in cervical cancer incidence among women with normal cytological screening results. We therefore performed a nationwide assessment of false-negative cytology before invasive cervical cancer. The Swedish national cervical screening registry identified 2,150 normal cytologies taken up to 10 years before 903 cases of invasive cervical cancer. The 27 cytological laboratories in Sweden were asked to rereview the slides, and all of them completed the rereview. One thousand nine hundred fifteen slides were retrieved and reviewed. Abnormalities were found in 30% of the slides, and the proportion of slides that had a changed diagnosis on rereview increased on average by 3.9% per sampling year during 2001–2016 (<i>p</i> &#x3c; 0.03). We also asked for rereview of normal smears taken up to 42 months before a histopathologically diagnosed high-grade squamous intraepithelial lesion (HSIL) or adenocarcinoma in situ (AIS). 19/27 laboratories responded, and out of 6,101 normal smears taken before HSIL/AIS, 5,918 were retrieved and rereviewed. The diagnosis was changed in 25% of cases. In summary, we found an increasing time trend of false-negative smears taken before invasive cervical cancer. This indicates a decreased protection of normal cytology in the screening program supporting earlier findings that this is the main reason behind the recent Swedish increase in cervical cancer. We suggest that optimal cervical cancer control may be promoted by routine nationally coordinated rereview of negative smears before high-grade cervical lesions or invasive cervical cancer.

Cervical neoplasia

2019 ◽  
pp. 357-364
Keyword(s):  
Cervical Cancer ◽  
Screening Program ◽  
Cervical Screening ◽  
Hpv Vaccination ◽  
Invasive Cervical Cancer ◽  
Intraepithelial Neoplasia ◽  
Cervical Neoplasia ◽  
Women Living With Hiv ◽  
The Bethesda System ◽  
Common Malignancy

Cervical neoplasia provides an overview of the 4th most common malignancy in women worldwide, including the premalignant phase. Specific terminology used in cytology and histology (including atypia, dyskaryosis, cervical intraepithelial neoplasia (CIN), cervical glandular intraepithelial neoplasia (CGIN) and invasive cervical cancer (ICC) are explained, and the epidemiology and risk factors (with an emphasis on human papilloma virus (HPV)) for this common malignancy are included. Clinical presentation is outlined. Cervical screening is discussed, including the role of HPV testing, and both the British Association for Cytopathology/NHS cervical screening program 2013 classification of cervical cytology and the Bethesda system (used more widely worldwide) are explained. Diagnosis includes colposcopic examination of the cervix, and the management of both CIN and cervical cancer are included. HPV vaccination, pregnancy, and women living with HIV (including ICC as AIDS-defining) are discussed.

scholarly journals The role of human papillomavirus genotyping for detecting high-grade intraepithelial neoplasia or cancer in HPV-positive women with normal cytology: A study from a hospital in northeastern China

2020 ◽  
Author(s):  
Jing Zhang ◽  
Deyu Zhang ◽  
Zhuo Yang ◽  
Xiaobin Wang ◽  
Danbo Wang
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Intraepithelial Neoplasia ◽  
Northeastern China ◽  
Adenocarcinoma In Situ ◽  
High Grade ◽  
Normal Cytology ◽  
Hpv Genotyping ◽  
High Risk Hpv

Abstract Background: Human papillomavirus (HPV) testing is more sensitive than cytology for detecting cervical cancer and its precursors. This study aimed to analyze the prevalence of high-risk HPV genotypes and evaluate the role of HPV genotyping triage for detecting high-grade squamous intraepithelial lesions, adenocarcinoma in situ and cervical cancer (HSIL+) in HPV-positive women with normal cytology. Methods: A retrospective study was performed in women who had undergone co-screening at the China Medical University-affiliated Shengjing Hospital between 2012 and 2014. Results: Of the 34,587 women, 2,665 HPV-positive women with normal cytology who had received colposcopy were eligible for analysis. In HSIL+ groups of 204 women, the common genotypes were HPV16, HPV52, HPV58, HPV33, HPV31 and HPV18. The proportion of histological HSIL+ in women infected with HPV33 or HPV31 was not significantly different compared to women infected with HPV16 ( P = 0.30, P = 0.19, respectively).The odds ratios for histological HSIL+ were 3.26 (95% confidence interval [CI]: 2.41–4.40) in women with HPV16/18, 4.21 (95% CI: 2.99–5.93) in those with HPV16/18/31/33, and 5.73 (95% CI: 3.30–9.97) in those with HPV16/18/31/33/52/58. Including HPV31/33 genotyping together with HPV16/18 significantly increased the proportion of HSIL+ detection from 63.2% to 77.5% ( P = 0.002). Moreover, the colposcopy per HSIL+ detection ratio only slightly increased from 7.7 to 8.1 ( P = 0.66). Conclusion: HPV genotyping played an important role in managing HPV-positive women with normal cytology. Genotyping for HPV31/33 should be added to the previously recommended HPV16/18 genotyping in triaging HPV-positive women in northeastern China.

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update

2007 ◽  
Vol 121 (3) ◽  
pp. 621-632 ◽  
Author(s):  
Jennifer S. Smith ◽  
Lisa Lindsay ◽  
Brooke Hoots ◽  
Jessica Keys ◽  
Silvia Franceschi ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Meta Analysis ◽  
Invasive Cervical Cancer ◽  
High Grade ◽  
Cervical Lesions ◽  
Type Distribution

scholarly journals HPV Detection Methods

2007 ◽  
Vol 23 (4) ◽  
pp. 273-281 ◽  
Author(s):  
Antoinette A. T. P. Brink ◽  
Peter J. F. Snijders ◽  
Chris J. L. M. Meijer
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
High Risk ◽  
Cervical Intraepithelial Neoplasia ◽  
Causal Relation ◽  
Cervical Screening ◽  
Intraepithelial Neoplasia ◽  
Detection Methods ◽  
High Grade ◽  
Cervical Lesions

Given the causal relation between a persistent high-risk human papillomavirus (hrHPV) infection and the development of high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer, hrHPV testing has been advocated in addition to cytology for the detection of clinically relevant cervical lesions. HrHPV testing is thought to improve cervical screening algorithms, the management of women with cytologically equivocal smears, and the management of women treated for high grade CIN. In this chapter we discuss different methods for HPV detection and genotyping and their respective applications.

EPIDEMIOLOGY OF CERVICAL CANCER IN THE REPUBLIC OF KAZAKHSTAN FOR 10 YEARS (2007-2016)

2017 ◽  
Vol 63 (4) ◽  
pp. 572-579
Author(s):  
Dilyara Kaydarova ◽  
M. Kayrbaev ◽  
R. Bolatbekova
Keyword(s):  
Cervical Cancer ◽  
Detection Rate ◽  
Screening Program ◽  
Gynecological Cancer ◽  
Cervical Screening ◽  
Invasive Cervical Cancer ◽  
Significant Risk ◽  
Incidence Rates ◽  
Female Population ◽  
The Republic

Invasive cervical cancer is the most common form of gynecological cancer in Kazakhstan, which occupies the 5th position among all neoplasias and the 10th place in mortality of the general population. The national cervical screening program in the Republic of Kazakhstan uses cytology (Pap test) from 2008, which is free of charge for women aged 30 to 60 years with an interval of 5 years. In the analysis of intensive incidence rates of cervical cancer it is noted an increase in the detection rate of this disease in the period from 2007 to 2016: in 2007 the incidence was 15.3 per 100 000 female population, and in 2016 to 19.1 per 100 000 female population. The analysis of age in incidence rates showed a significant risk of the disease at a young age and a noticeable increase it to 4044 years. In the analysis of cervical cancer in the context of the stages it is marked an increase in the detection rate of the disease in the first stage, for the period from 2007 to 2016.

scholarly journals Detection of gene amplification in MYCN, C-MYC, MYCL1, ERBB2, EGFR, AKT2, and human papilloma virus in samples from cervical smear normal cytology, intraepithelial cervical neoplasia (CIN I, II, III), and cervical cancer

2011 ◽  
pp. 144-153
Author(s):  
Dabeiba Adriana García ◽  
Ignacio Briceño ◽  
Marcos Castillo ◽  
Fabio Ancizar Aristizábal
Keyword(s):  
Cervical Cancer ◽  
Gene Amplification ◽  
Intraepithelial Neoplasia ◽  
Low Grade ◽  
High Grade ◽  
Cancer Genes ◽  
Cervical Lesions ◽  
Normal Cytology ◽  
Papilloma Virus ◽  
Cin Iii

Introduction: Cervical cancer is the second most common cancer among women worldwide and the second cause of cancer mortality in women. It has been demonstrated that the process of cervical carcinogenesis displays genetic and environmental epigenetic components. Currently, research is focused on new prognosis markers like oncogene amplification. Objectives: To perform detection of MYCN, C-MYC, MYCL1, ERBB2, EGFR, and AKT2 amplification. Additionally, to detect human papillomavirus in samples from normal cytology smear, cervical intraepithelial neoplasia (CIN) I, II, and III and cervical cancer patients. Methods: Papillomavirus (HPV) genotyping by reverse line blot (RLB) performed and gene amplification by detection with real-time PCR with Taqman probes. Results: HPV was present in 4% of the patients with normal cytology, 48% in CIN I, 63.6% in CIN II, 64% in CIN III, and 70.8% in cervical cancer. Genes amplified in cervical cancer were MYCN (39.1%), ERBB2 (34.7%), and MYCL1 (30.4%); showed higher amplification in high-grade lesions and cervical cancer in relation to low-grade lesions and normal cytology with statistically significant differences. Besides the genes, C-MYC, EGFR, and AKT2 were amplified in samples from patients with cervical cancer by 12%, 18%, and 13%, respectively; we did not find statistical differences. Conclusion: Higher prevalence of gene amplification and HPV was found in high-grade cervical lesions and cervical cancer.

scholarly journals The role of human papillomavirus genotyping for detecting high-grade intraepithelial neoplasia or cancer in HPV-positive women with normal cytology: a study from a hospital in northeastern China

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Jing Zhang ◽  
Deyu Zhang ◽  
Zhuo Yang ◽  
Xiaobin Wang ◽  
Danbo Wang
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Intraepithelial Neoplasia ◽  
Northeastern China ◽  
Adenocarcinoma In Situ ◽  
High Grade ◽  
Normal Cytology ◽  
Hpv Genotyping ◽  
High Risk Hpv

Abstract Background Human papillomavirus (HPV) testing is more sensitive than cytology for detecting cervical cancer and its precursors. This study aimed to analyze the prevalence of high-risk HPV genotypes and evaluate the role of HPV genotyping triage for detecting high-grade squamous intraepithelial lesions, adenocarcinoma in situ and cervical cancer (HSIL+) in HPV-positive women with normal cytology. Methods A retrospective study was performed in women who had undergone co-screening at the China Medical University-affiliated Shengjing Hospital between 2012 and 2014. Results Of the 34,587 women, 2665 HPV-positive women with normal cytology who had received colposcopy were eligible for analysis. In HSIL+ groups of 204 women, the common genotypes were HPV16, HPV52, HPV58, HPV33, HPV31 and HPV18 in order of prevalence. The proportion of histological HSIL+ in women infected with HPV33 or HPV31 was not significantly different compared to women infected with HPV16 (P = 0.30, P = 0.19, respectively). The odds ratios for histological HSIL+ were 3.26 (95% confidence interval [CI]: 2.41–4.40) in women with HPV16/18, 4.21 (95% CI: 2.99–5.93) in those with HPV16/18/31/33, and 5.73 (95% CI: 3.30–9.97) in those with HPV16/18/31/33/52/58. Including HPV31/33 genotyping together with HPV16/18 significantly increased the proportion of HSIL+ detection from 63.2 to 77.5% (P = 0.002) without significantly increasing the colposcopy per HSIL+ detection ratio (7.7 to 8.1, P = 0.66). Conclusions HPV genotyping played an important role in managing HPV-positive women with normal cytology. Genotyping for HPV31/33 should be added to the previously recommended HPV16/18 genotyping in triaging HPV-positive women in northeastern China.

Sign in / Sign up

Export Citation Format

Share Document